Global Intravenous Injection General Anesthesia Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Intravenous Injection General Anesthesia Drugs Market Research Report 2024
Intravenous general anesthesia refers to a method in which one or several drugs are injected intravenously and act on the central nervous system through blood circulation to produce general anesthesia. According to different administration methods, intravenous anesthesia can be divided into single administration method, divided administration method and continuous administration method. Due to some limitations of its own, the use of intravenous general anesthesia was once limited. However, since the 1980s, with the continuous improvement of clinical pharmacology research methods, the development of new strong and short-acting intravenous anesthetics and the advent of computerized intravenous automatic drug delivery systems, intravenous anesthesia has been greatly improved. And development, has now become the mainstream general anesthesia solution.
According to Mr Accuracy reports’s new survey, global Intravenous Injection General Anesthesia Drugs market is projected to reach US$ 2444.1 million in 2029, increasing from US$ 1584 million in 2022, with the CAGR of 6.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Intravenous Injection General Anesthesia Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Intravenous Injection General Anesthesia Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Aspen Pharma
Fresenius-Kabi
AbbVie
Baxter Healthcare
B.Braun
Maruishi
Piramal
Hikma Pharmaceuticals
AstraZeneca
Nhwa
Hengrui
Xi'an Libang
Yichang Humanwell
China National Medicines Guorui Pharmaceutical Co.,Ltd.
Maruishi
Lunan Pharmaceutical Group Corporation
Segment by Type
Propofol
Sevoflurane
Remifentanil
Etomidate
Isoflurane
Other
Hopitals
Clinics
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Intravenous Injection General Anesthesia Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Intravenous Injection General Anesthesia Drugs market is projected to reach US$ 2444.1 million in 2029, increasing from US$ 1584 million in 2022, with the CAGR of 6.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Intravenous Injection General Anesthesia Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Intravenous Injection General Anesthesia Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Aspen Pharma
Fresenius-Kabi
AbbVie
Baxter Healthcare
B.Braun
Maruishi
Piramal
Hikma Pharmaceuticals
AstraZeneca
Nhwa
Hengrui
Xi'an Libang
Yichang Humanwell
China National Medicines Guorui Pharmaceutical Co.,Ltd.
Maruishi
Lunan Pharmaceutical Group Corporation
Segment by Type
Propofol
Sevoflurane
Remifentanil
Etomidate
Isoflurane
Other
Segment by Application
Hopitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Intravenous Injection General Anesthesia Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices